Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Mitomycin-C and capecitabine (MIXE) as salvage treatment in patients with refractory metastatic colorectal cancer: a retrospective study.

Saif MW, Kaley K, Brennan M, Garcon MC, Rodriguez G.

Anticancer Res. 2013 Jun;33(6):2743-6.

PMID:
23749935
2.

Mitomycin C and high-dose 5-fluorouracil with folinic acid as a therapeutic option for heavily pretreated patients with metastatic colorectal cancer: prospective phase II trial.

Stec R, Bodnar L, Smoter M, Korniluk J, Kuchar A, Młot B, Szczylik C.

Oncologist. 2014 Apr;19(4):356-7. doi: 10.1634/theoncologist.2014-0029. Epub 2014 Mar 28.

3.

Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.

Lim DH, Park YS, Park BB, Ji SH, Lee J, Park KW, Kang JH, Lee SH, Park JO, Kim K, Kim WS, Jung CW, Im YH, Kang WK, Park K.

Cancer Chemother Pharmacol. 2005 Jul;56(1):10-4. Epub 2005 Mar 22.

PMID:
15782313
4.

Capecitabine in combination with docetaxel and mitomycin C in patients with pre-treated tumours: results of an extended phase-I trial.

Ernst T, Merx K, Gnad-Vogt U, Lukan N, Kripp M, Schultheis B, Hochhaus A, Hofheinz RD.

Br J Cancer. 2007 Dec 3;97(11):1475-9. Epub 2007 Nov 13.

5.

Mitomycin C plus capecitabine (mixe) in anthracycline- and taxane-pretreated metastatic breast cancer. A multicenter phase II study.

Maisano R, Caristi N, Mare M, Raffaele M, Iorfida M, Mafodda A, Zavettieri M, Nardi M.

Anticancer Res. 2007 Jul-Aug;27(4C):2871-5.

7.

Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.

Lee JJ, Kim TM, Yu SJ, Kim DW, Joh YH, Oh DY, Kwon JH, Kim TY, Heo DS, Bang YJ, Kim NK.

Jpn J Clin Oncol. 2004 Jul;34(7):400-4.

PMID:
15342667
8.

The efficacy of gemcitabine as salvage treatment in patients with refractory advanced colorectal cancer (CRC): a single institution experience.

Saif MW, Kaley K, Penney R, Hotchkiss S, Syrigos KN, Strimpakos AS.

Anticancer Res. 2011 Sep;31(9):2971-4.

PMID:
21868546
10.

Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.

Jones A, O'Brien M, Sommer H, Nowara E, Welt A, Pienkowski T, Rolski J, Pham ML, Perraud K, Trillet-Lenoir V.

Cancer Chemother Pharmacol. 2010 Mar;65(4):755-63. doi: 10.1007/s00280-009-1081-y. Epub 2009 Aug 9.

PMID:
19669644
11.

Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer.

Lim T, Lee J, Lee DJ, Lee HY, Han B, Baek KK, Ahn HK, Lee SJ, Park SH, Park JO, Park YS, Lim HY, Kim KM, Kang WK.

Cancer Chemother Pharmacol. 2011 Jul;68(1):255-62. doi: 10.1007/s00280-011-1653-5. Epub 2011 Apr 28.

12.

Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer.

Conti JA, Kemeny NE, Saltz LB, André AM, Grossano DD, Bertino JR.

Cancer. 1995 Feb 1;75(3):769-74.

13.

Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.

Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA.

Breast Cancer Res Treat. 2012 Jan;131(1):111-6. doi: 10.1007/s10549-011-1749-y. Epub 2011 Sep 4.

PMID:
21898114
14.
15.

Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.

Rao S, Cunningham D, Price T, Hill ME, Ross PJ, Tebbutt N, Norman AR, Oates J, Shellito P.

Br J Cancer. 2004 Aug 31;91(5):839-43.

16.

Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study.

Tebbutt NC, Wilson K, Gebski VJ, Cummins MM, Zannino D, van Hazel GA, Robinson B, Broad A, Ganju V, Ackland SP, Forgeson G, Cunningham D, Saunders MP, Stockler MR, Chua Y, Zalcberg JR, Simes RJ, Price TJ.

J Clin Oncol. 2010 Jul 1;28(19):3191-8. doi: 10.1200/JCO.2009.27.7723. Epub 2010 Jun 1.

PMID:
20516443
17.

Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma.

Hoff PM, Pazdur R, Lassere Y, Carter S, Samid D, Polito D, Abbruzzese JL.

J Clin Oncol. 2004 Jun 1;22(11):2078-83.

PMID:
15169794
18.

Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.

Hong YS, Lee J, Lee SC, Hwang IG, Choi SH, Heo JS, Park JO, Park YS, Lim HY, Kang WK.

Cancer Chemother Pharmacol. 2007 Aug;60(3):321-8. Epub 2006 Dec 2.

PMID:
17143602
19.

[Efficacy and safety of regimens of capecitabine-based chemotherapy in the treatment of advanced breast cancer].

Huang HY, Jiang ZF, Wang T, Zhang SH, Bian L, Cao Y, Wu SK, Song ST.

Zhonghua Zhong Liu Za Zhi. 2011 Nov;33(11):850-3. Chinese.

PMID:
22335952
20.

A phase I study of vinflunine in combination with capecitabine in patients with metastatic breast cancer previously treated with anthracyclines and taxanes.

Campone M, Isambert N, Bourbouloux E, Roché H, Bonneterre J, Milano G, Fumoleau P.

Cancer Chemother Pharmacol. 2012 Apr;69(4):871-9. doi: 10.1007/s00280-011-1767-9. Epub 2011 Nov 2.

PMID:
22045498

Supplemental Content

Support Center